此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Role of Perioperative Dexmedetomidine on Intraoperative Hemodynamics and Neuro-endocrine Response in Patients Undergoing Robot-Assisted Gynecological Surgery

2026年11月15日 更新者:Ain Shams University

The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.

研究概览

详细说明

The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.

  1. Pre-operative settings:

    Preoperative evaluation of full medical history, laboratory investigations in form of complete blood count, blood sugar, liver function tests, kidney function tests, serum electrolytes and coagulation profile and for fulfilling inclusion criteria. Patients will be trained how to use visual analogue scale (VAS).

    Patients will be divided into two groups:

    Group D :(n = 25) will receive (1 μg/kg) of dexmedetomidine as a loading intravenously for 10 min before anesthesia induction and will be continuously infused at 0.2 μg/kg/h intraoperatively.

    Group P: (n = 25) will receive The same volume of normal saline in the same manner to group D.

  2. Intraoperative Settings:

All patients will receive the standard technique of general anesthesia by the supervisors of the research. Two intravenous wide pore accesses will be secured, one for routine fluids and the other exclusively for Dex. All the patients will receive pantoprazole 40 mg and Ondansetron 4mg intravenously 15 min before induction and Loading dose of Dex infusion 1 mcg/kg will be started and continued for 10 minutes for group D and Normal saline with the same volume will be given to group P in the same manner.

ECG, non-invasive blood pressure and pulse oximeter will be established upon the patient's arrival in the operating room. Induction of anesthesia in both groups will be done by intravenous 1-2 mg/kg propofol, 1mic/kg fentanyl and 0.5 mg/kg atracurium.

Maintenance will be achieved with appropriate sized cuffed endotracheal tube passed orally, and the placement will be confirmed with auscultation and end-tidal carbon dioxide (EtCO2) reading. Anesthesia will be maintained with air and oxygen mixture (60:40), and isoflurane, using a closed circuit , top-up doses of atracurium , and the rate of Dex infusion will be changed to a maintenance infusion of 0.2 mcg/kg/h for group D and the same with normal saline for group P. End-tidal concentration of isoflurane will be monitored by measuring the average concentration and its total dosage through the infrared multi-gas analyzers. Vasopressor response to laryngoscopy and intubation will be documented by noting HR and BP. The lungs will be ventilated by maintaining a tidal volume of 6-8 ml/kg, and a respiratory rate to keep ETCO2 at 35-40 mmHg with continuous monitoring.

Intra-operative bradycardia (pulse rate <50) will be treated with atropine 0.6 mg.

Intra-operative hypotension will be treated with intravenous crystalloids and by reducing the isoflurane concentration and ephedrine. An increase in HR and/or mean arterial pressure (MAP) >20% from baseline values will be treated by 1 mcg/kg of intravenous fentanyl. If there will be no response within 5 min, the initial isoflurane concentration will be increased by 0.2% increment every 4 min up to a maximum of 1% end-tidal concentration. Any additional requirement of lapetalol or nitroglycerine to control BP will be noted Isoflurane inhalation will be stopped 10 min before the end of surgery and dexmedetomidine will be stopped at the end of skin incision closure. The total amount of fentanyl administered during each case will be also recorded.

Blood samples will be analyzed for blood Serum cortisol level, serum glucose and serum lactate.

Serum cortisol level preoperatively (baseline), just after incision, at 6 h after anesthesia induction, at 12 h after induction and at 24 h after induction.

Serum glucose level preoperatively (baseline), just after incision and at 6 h after anesthesia induction.

Serum lactate level preoperatively (baseline), just after incision, at 6 h after anesthesia induction and at 12 h after induction.

  1. Hemodynamic monitoring:

    Intraoperative monitoring was documented during the pre-induction, after the loading dose of Dex, at the induction of anesthesia, during laryngoscopy and intubation, and at pneumoperitoneum and then every 30 min till the end of surgery and continued during extubation and post operatively for 1 hr every 30 min.

  2. Assessment of post-operative pain & sedation:

By the end of surgery, anesthesia will be discontinued and reversal will be given (when full muscle power regained) as neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. Extubation will be done, and the patient will be transferred to the PACU.

研究类型

介入性

注册 (估计的)

50

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Hala said Hassan, MD
  • 电话号码:+201147784179

学习地点

    • Abbassia, Egypt
      • Cairo、Abbassia, Egypt、埃及
        • 招聘中
        • Ain Shams University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 至 60年 (成人)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Patients aged from 21-60 years.
  • Patients ASA I or II undergoing elective Robot-Assisted gynecological surgery under general anesthesia.

Exclusion Criteria:

  • Patient refusal.
  • ASA III and ASA IV.
  • A known history of allergy to the drugs used.
  • Patients on chronic steroid therapy.
  • Patient with cardiovascular disorder (Bradycardia, heart block, heart failure).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Group D (Dexmedetomidine)

Receives IV dexmedetomidine loading dose (1 μg/kg over 10 minutes before anesthesia induction) followed by a continuous infusion (0.2 μg/kg/h) until 15 minutes before the end of surgery.

IV loading dose of 1 μg/kg over 10 min prior to induction, then maintenance infusion of 0.2 μg/kg/h until 15 min prior to surgery end.

安慰剂比较:Group P (Placebo)

Receives normal saline in the same volume and infusion rate schedule as Group D (loading dose over 10 minutes before induction, followed by continuous infusion).

Equivalent volume of normal saline solution administered as an IV loading dose and continuous infusion matching the study drug timeline.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Serum Cortisol Level
大体时间:Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.

Evaluation of the perioperative neuro-endocrine stress response by measuring blood serum cortisol levels.

Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.

次要结果测量

结果测量
措施说明
大体时间
Time to First Rescue Analgesia
大体时间:Up to 24 hours postoperatively

The time interval between the completion of drug injection and the participant's first post-operative request for pain relief administered when Numerical Pain Distress Scale above 4 as • 0: No pain

  • 1-3: Mild pain
  • 4-6: Moderate pain
  • 7-10: Severe pain
Up to 24 hours postoperatively
Serum Glucose level
大体时间:Serum glucose: Baseline, just after incision, and 6 hours post-induction.

Blood serum level of glucose to assess metabolic stress.

Serum glucose: Baseline, just after incision, and 6 hours post-induction.
Numerical Pain Distress Scale (NPDS) Score
大体时间:Upon recovery in PACU and throughout the first 24 hours postoperatively.

Self-reported pain intensity scored on an 11-point scale (0 = No pain to 10 = Unbearable pain).

Higher number means high pain intensity.

Upon recovery in PACU and throughout the first 24 hours postoperatively.
Ramsay Sedation Scale Score
大体时间:Upon recovery in PACU and during the first 2 hours postoperatively.

Assessment of sedation level scored from 1 (anxious or restless) to 6 (no response to stimulus).

Upon recovery in PACU and during the first 2 hours postoperatively.
Intraoperative Analgesic Consumption
大体时间:Intraoperatively measured from induction till end of surgery.

Total intraoperative fentanyl consumption.

Intraoperatively measured from induction till end of surgery.
Intraoperative Mean Arterial Pressure (MAP)
大体时间:Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response.

Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.
Incidence of Side Effects and Complications
大体时间:Up to 24 hours postoperatively.

Occurrence of postoperative nausea, vomiting, bradycardia, hypotension, or respiratory depression.

It will be recorded as yes or No .

Up to 24 hours postoperatively.
Lactate Level
大体时间:Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.

Blood serum lactate level to assess metabolic stress.

Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.
Postoperative Analgesic Consumption
大体时间:through 24 hours postoperatively.

Total postoperative meperidine consumption.

through 24 hours postoperatively.
Intraoperative Anesthetic Consumption
大体时间:Intraoperatively measured from induction till end of surgery.

Total intraoperative consumption of isoflurane and average end-tidal concentration

Intraoperatively measured from induction till end of surgery.
Intraoperative Heart Rate (HR)
大体时间:Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response.

Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月10日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2026年9月13日

首先提交符合 QC 标准的

2026年11月15日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月15日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be publicly shared in an open repository to protect participant privacy. Aggregate data and trial results will be published in a peer-reviewed journal upon study completion.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅